论文部分内容阅读
强心甙应用到临床己有二百年历史,至今仍然是治疗充血性心力衰竭不可缺少的药物。现在临床上常用的强心甙类制剂已有五、六种,它们的作用虽有强弱、快慢和久暂的不同,但这些药物都有共同的缺点--治疗宽度过于狭窄,有时效力也嫌不足。由于治疗宽度狭窄,临床上强心甙中毒的发生率很高,人们迫切需要一种安全而有效的强心药物。目前,国外对强心甙的研究主要集中在药物作用的生化机制、药代动力学和临床药理方面。近年来,我国发现了一些具有扩冠、降血脂和抗心律失常作用的新药,但至今没有发现在临床应用上可以取代洋地黄的药物。本文将对寻找新药的必要性和可能性以及发现新药的途径进行阐述。
Cardiac glycosides have been applied to the clinical two hundred years of history, is still an indispensable drug for the treatment of congestive heart failure. Now commonly used in clinical cardiac glycosides formulations have been five or six, although their role in the strength, speed and duration of the different, but these drugs have a common shortcomings - the treatment is too narrow and sometimes too effective insufficient. Due to the narrow treatment width, the incidence of clinical cardiac glycoside poisoning is very high, people urgently need a safe and effective cardiac drug. At present, the research on cardiac glycosides in foreign countries mainly focuses on the biochemical mechanism, pharmacokinetics and clinical pharmacology of the drug. In recent years, some new drugs have been found in our country that have the functions of expanding the coronary artery, lowering blood fat and anti-arrhythmia, but so far no drugs that can replace digitalis in clinical application have been found. This article will elaborate on the necessity and possibility of finding new drugs and ways of discovering new drugs.